Biologically informed deep neural network for prostate cancer discovery
Source check: Needs source check. Not independent scientific confirmation.
Finding: P-NET, a pathway-structured neural network, was trained on molecular data to stratify prostate cancer by treatment-resistance state. Its interpretation highlighted established and novel candidates, including MDM4 and FGFR1, which the authors report validating in vitro.
Technology: P-NET, a biologically informed interpretable deep neural network
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- Interpretable network weights prioritised molecular drivers of advanced disease.
- Test and result
- Abstract reports superior prediction versus other models and in vitro validation of MDM4 and FGFR1.
- Limitation / still unknown
- Clinical utility and independent replication not assessed (abstract only).
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://europepmc.org/search?query=DOI:10.1038/s41586-021-03922-4
Needs source check · editorial details
The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 17 Nov 2026. Review scope: Europe PMC metadata and abstract only; Methods not read..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.